A Phase 2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety of Niraparib in Japanese Patients With Platinum-sensitive, Relapsed Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Achieved CR or PR in the Last Chemotherapy Containing Platinum-based Anticancer Agents
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2019
Price : $35 *
At a glance
- Drugs Niraparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Takeda
- 11 Apr 2019 Planned End Date changed from 13 Jan 2021 to 3 Nov 2020.
- 22 Feb 2019 Planned End Date changed from 30 Apr 2021 to 13 Jan 2021.
- 22 Feb 2019 Planned primary completion date changed from 30 Apr 2020 to 24 May 2019.